Add to Calendar
8/26/2020 8:00:00 AM8/27/2020 5:00:00 PM 2020 State of Possible Conference
Special thanks to our Platinum Sponsor Morgan Stanley
Registered attendees will receive an email with the subject line “Welcome to the State of Possible Conference 2020 - Event Access Link” from email@example.com.
The State of Possible Conference, MassBio's Annual Meeting, will now be hosted virtually on August 26-27, 2020. Featuring interactive networking and a groundbreaking viewer experience, this event will not be your average webinar.
We will celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks®, inspiring and engaging content in the style of a TED Talk.
"It's the Woodstock of Life Sciences, with all-star performers playing their greatest hits all on one stage.” – 2019 State of Possible Conference attendee
If you haven’t attended our State of Possible Conference before, it is the premier east coast life sciences conference. We have some of the brightest names in biotech talking about the issues impacting our industry, covering topics from the realities of precision medicine to advancing new drug targets faster.
NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
Online Conference, Link will be sent in advance of the event.
AVP, Computational and Structural Chemistry, Merck Research Labs
Dr. Juan Alvarez is the AVP of Computational and Structural Chemistry at Merck Research Labs, leading the computational chemistry, cheminformatics, and protein structure determination groups supporting the end to end discovery and early development pipeline. Prior to Merck, Juan was at Alkermes from 2010-2017, where he established and led biologics discovery at Alkermes, advancing ALKS 4230 into the clinic as an immuno-oncology agent. From 2004 to 2010, Juan led Automation Technologies for TransForm Pharmaceuticals (acquired by J&J in 2005), where his team built and applied integrated high throughput lab robotics and big data informatics towards the formulation of small molecules, proteins, and vaccines. Juan also served as the Head of Computational Chemistry for Wyeth Research and Genetics Institute between 1992 and 2004. Juan received his Ph.D. in Pharmaceutical Chemistry from UCSF and an S.B. in Chemistry from MIT.